化合物 Droxidopa hydrochloride T60369

Product Introduction
Bioactivity


英文名: Droxidopa hydrochloride

描述: Droxidopa (L-DOPS) hydrochloride 是一种有效的、具有口服活性的去甲肾上腺素前体。Droxidopa hydrochloride 可增加站立血压，改善直立性低血压症状并提高站立能力。Droxidopa hydrochloride 具有研究神经源性直立性低血压（nOH）和替代性多动症 (注意缺陷多动障碍) 的潜力[3]。

体内活性: Droxidopa hydrochloride (200 mg/kg;i.p.) alters dopamine neuron and prefrontal cortex activity and improves attention-deficit/hyperactivity disorder-like behaviors in rats [2]. Droxidopa hydrochloride (10, 20 mg/kg; i.p.) significantly increases the paw withdrawal latency and suppresses mechanical hypersensitivity to thermal stimulation in 6-OHDA-lesioned rats at the 5th week after surgery [3]. Animal Model: 250-380g male Sprague-Dawley rats [2] Dosage: 200 mg/kg (10 mg/kg, i.p. benserazide was given to the animals at 20 or 30 min prior to L-DOPS injection) Administration: I.p. Result: Significantly decreased hyperactivity of BZ-pretreated SHR/NCrl at 30 (P < 0.01) and 40 min (P < 0.05) post-injection, improved inattention-like behavior of SHR/NCrl, and ameliorated impulsive-like behavior of SHR/NCrl and Wistar rats.

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

化合物 Droxidopa hydrochloride T60369信息由TargetMol中国为您提供，如您想了解更多关于化合物 Droxidopa hydrochloride T60369报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途